There is a large variety in prevalence, clinicopathological features and management of lupus nephritis (LN) between patients worldwide. Data from North Africa are extremely lack, particularly from Morocco. The aim of this retrospective study was to describe clinicopathological features as well as treatment and outcome of patients with biopsy proven LN in a region of Morocco. A total of 54 patients were included between January 2008 and December 2018. LN was classified according to the International society of Nephrology/Renal Pathology Society. The mean age of the patients was 28+/-11, 76; female gender was preponderant (91%). At first presentation, hypertension, hematuria, proteinuria and renal failure were observed in 74%, 74%, 83% and 48% respectively. Renal biopsy performed in all patients revealed proliferative classes in 76%. Conservatively treatment was adopted in all patients. 61% of patients with joint and mucocutaneous manifestations received antimalarial drug. All patients with proliferative classes received immunosuppressive regimens based on either intravenous cyclophosphamide (43%) or oral mycophenolate mofetil (33%). At 6 months, remission was achieved in 85%, end stage renal disease in 4% and death in 6%. Adverse events due to immunosuppressive drugs were mostly dominated by infections (41%), leukopenia (20%) gastrointestinal symptoms (31%) and gonadal toxicity (24%). From our view, the outcome of Moroccan patients with LN may be better than commonly thought. However, disparities seen from several studies in our country can be assigned to the precariousness of health system and the low socioeconomic level of population.